In a major breakthrough for eye care, the U.S. Food and Drug Administration (FDA) has approved LENZ Therapeutics’ innovative eye drops designed to correct presbyopia, a common age-related condition that makes it difficult to see things up close.
Presbyopia typically affects people over 40 and is caused by the eye’s lens becoming less flexible, making it harder to focus on nearby objects. Until now, the most common solution has been reading glasses or corrective lenses. But this new approval offers a non-invasive alternative.
How Do the Eye Drops Work?
The eye drops, called LNZ100 and LNZ101, use pilocarpine, a medication that temporarily shrinks the pupil. This increases depth of field and improves the eye’s ability to focus on close objects — without affecting distance vision. Applied once a day, the drops begin working in as little as 15 minutes and can last for 6–8 hours, offering users daily freedom from glasses.
According to LENZ Therapeutics, clinical trials showed significant improvement in near vision for most users. The company plans to launch the product commercially soon, potentially transforming how millions manage presbyopia.
A Growing Market
With nearly 128 million Americans affected by presbyopia, the approval marks a pivotal step in the growing field of pharmaceutical vision correction. LENZ Therapeutics joins a small but expanding group of companies aiming to provide non-surgical, drug-based solutions to common eye conditions.
This innovation could pave the way for more personalized, convenient, and less intrusive treatments for vision problems in the near future.
Article source by Industrytap
Image source by Towfiqu barbhuiya on Unsplash
